EMA Application withdrawn: Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride) — Laboratorios Tillomed Spain S.L.U

View source ↗

Summary

The EMA withdrew the application for doxorubicin hydrochloride from Laboratorios Tillomed Spain S.L.U. for several cancer indications including breast and ovari…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Multiple Myeloma
• Ovarian Neoplasms
• Sarcoma Kaposi

Drugs mentioned

• Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride)

Snippet

Status: Application withdrawn. Therapeutic area: Breast Neoplasms;Ovarian Neoplasms;Multiple Myeloma;Sarcoma, Kaposi. MAH: Laboratorios Tillomed Spain S.L.U. Decision date: 27/02/2020